Century Therapeutics: A Very Promising Contender In The Type I Diabetes Mellitus Functional Cure Race

Century Therapeutics (IPSC) aims at a durable “once-and-done” Type 1 diabetes cure with hypoimmune iPSC beta cells; runway to 2029—click here to read now.

The Income Method: How To Use Cash Flow To Fund Your Retirement

Good investors know patience is a virtue. Read more about building a diversified, resilient retirement income portfolio with ...
AHA/ASA Journals

Coronary Atherosclerosis in Patients With Cancer and Survivors: A Scientific Statement From the American Heart Association

There is an emerging convergence between atherosclerotic cardiovascular disease and cancer, driven by shared risk factors and overlapping pathophysiologic mechanisms. Traditional factors, such as ...
IEEE

Submillimeter Acoustic Vibration Measurement and Monitoring Using a Single Smartphone

Abstract: The accurate vibration measurement is crucial for monitoring and diagnosing industrial equipment. Existing solutions require either installing contact ...
BioSpace

Following Sarepta Woes, Others Look To Unlock the Next Chapter in DMD Treatment

With a clutch of key data and planned regulatory applications this year from Avidity Biosciences, REGENXBIO and Capricor ...
Conventus Law

Hong Kong – The Northbound Program Trading Reporting Rules Take Effect: Key Takeaways of the HKEX FAQ.

Hong Kong - The Northbound Program Trading Reporting Rules Take Effect: Key Takeaways of the HKEX FAQ. Legal News and ...

Affinia Therapeutics Announces FDA Acceptance of IND Application to Advance AFTX-201 to a Phase 1/2 Trial for the Treatment of BAG3-Associated Dilated Cardiomyopathy (DCM)

The UPBEAT (c) clinical trial is a multicenter, open-label Phase 1/2 clinical trial designed to evaluate the safety, tolerability, pharmacodynamics, and preliminary efficacy of AFTX-201 in adults with ...